Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17068139 | 0.83 | POLB (0.48) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL20612845 | 0.83 | POLB (0.48) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| Hydrochloric Acid SCHEMBL10692531 | 0.82 | GBA1 (0.53) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| Hydrochloric Acid SCHEMBL6951430 | 0.82 | GBA1 (0.53) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL18045353 | 0.81 | FKBP1A (0.39) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL18070759 | 0.81 | FKBP1A (0.39) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL2768950 | 0.78 | FKBP1A (0.54) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL980704 | 0.75 | HTR1A (0.40) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL980703 | 0.75 | HTR1A (0.40) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL28878129 | 0.74 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDNPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268366-A1 | (INDAZOL-4-YL)HEXAHYDROPYRROLOPYRROLONES AND METHOD OF USE | AbbVie Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9682985-B2 | (Indazol-4-yl) hexahydropyrrolopyrrolones and methods of use | ABBVIE INC. (US) | 2017-06-20 | — | — | US | disclosed |
| WO-2016149169-A1 | (INDAZOL-4-YL)HEXAHYDROPYRROLOPYRROLONES AND METHOD OF USE | ABBVIE INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160264582-A1 | (Indazol-4-YL) Hexahydropyrrolopyrrolones and Methods of Use | ABBVIE INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264582-A1 | (Indazol-4-YL) Hexahydropyrrolopyrrolones and Methods of Use | CACNA1D, CACNA1S, KCNJ11 | ALDH1A1 541/4885MAPT 4551/4885HPGD 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.